New pill aims to control prostate cancer with fewer side effects
NCT ID NCT02972060
Summary
This study is testing if a new oral drug, darolutamide, can control prostate cancer as effectively as standard hormone therapy (ADT) over 24 weeks. It will compare how well the drug lowers PSA levels and will closely track side effects and quality of life. The goal is to see if this pill offers a similar level of disease control but with a better side effect profile for men who have not yet received hormone treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Citta della Salute e della Scienza di Torino - Ospedale Molinette
Torino, 10126, Italy
-
CHU Dinant Godinne - UCL Namur
Yvoir, 5530, Belgium
-
CHU de Dijon - Centre Georges-Francois-Leclerc
Dijon, 21079, France
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Fundacion Instituto Valenciano De Oncologia
Valencia, 46009, Spain
-
Gustave Roussy
Villejuif, 94805, France
-
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, 1070, Belgium
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen De La Victoria
Málaga, 29010, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol
Badalona, 08916, Spain
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
Conditions
Explore the condition pages connected to this study.